MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions
- PMID: 12438311
- DOI: 10.1074/jbc.M209590200
MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions
Abstract
The importance of Thomsen-Friedenreich antigen (T antigen)-galectin-3 interactions in adhesion of human breast carcinoma cells to the endothelium under conditions of flow was studied. Highly metastatic cells (MDA-MB-435) expressing high levels of both galectin-3 and T antigen demonstrated significantly increased adhesion to monolayers of endothelial cells compared with their non-metastatic counterpart (MDA-MB-468) in vitro. Within minutes of adhesion, the highly metastatic cells acquire the ability of enhanced homotypic adhesion, leading to the formation of multicellular aggregates at sites of attachment to endothelial cells in vitro. Treatment of cells with lactulosyl-l-leucine, a synthetic T antigen antagonist that targets galectin-3 by mimicking T antigen, caused a 60-80% inhibition of both homo- and heterotypic adhesion of MDA-MB-435 cells. Confocal microscopy and fluorescence-activated cell sorter analysis revealed redistribution of endothelial galectin-3 to the site of heterotypic intercellular contacts, whereas galectin-3 in MDA-MB-435 cells accumulated at sites of homotypic interaction. MDA-MB-435 cells also exhibited increased adhesion and intravascular retention within the microvessels of transplanted lung allografts in nude mice. T antigen and galectin-3-mediated interactions of metastatic cancer cells with endothelium under conditions of flow are characterized by a unique adhesion mechanism that qualitatively distinguishes their homo- and heterotypic adhesive behavior from other cell types such as leukocytes.
Similar articles
-
Effects of Thomsen-Friedenreich antigen-specific peptide P-30 on beta-galactoside-mediated homotypic aggregation and adhesion to the endothelium of MDA-MB-435 human breast carcinoma cells.Cancer Res. 2000 May 15;60(10):2584-8. Cancer Res. 2000. PMID: 10825125
-
Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium.Cancer Res. 2003 Jul 1;63(13):3805-11. Cancer Res. 2003. PMID: 12839977
-
Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion.Carcinogenesis. 2005 Feb;26(2):309-18. doi: 10.1093/carcin/bgh329. Epub 2004 Nov 4. Carcinogenesis. 2005. PMID: 15528216
-
The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression.Glycoconj J. 2007 Nov;24(8):411-20. doi: 10.1007/s10719-007-9034-3. Epub 2007 Apr 25. Glycoconj J. 2007. PMID: 17457671 Review.
-
The role of TF- and Tn-antigens in breast cancer metastasis.Histol Histopathol. 2016 Jun;31(6):613-21. doi: 10.14670/HH-11-722. Epub 2016 Jan 13. Histol Histopathol. 2016. PMID: 26758176 Review.
Cited by
-
Altered melanoma cell surface glycosylation mediates organ specific adhesion and metastasis via lectin receptors on the lung vascular endothelium.Clin Exp Metastasis. 2005;22(1):11-24. doi: 10.1007/s10585-005-2036-2. Clin Exp Metastasis. 2005. PMID: 16132574
-
Binding of galectin-1 (gal-1) to the Thomsen-Friedenreich (TF) antigen on trophoblast cells and inhibition of proliferation of trophoblast tumor cells in vitro by gal-1 or an anti-TF antibody.Histochem Cell Biol. 2006 Oct;126(4):437-44. doi: 10.1007/s00418-006-0178-1. Epub 2006 Apr 11. Histochem Cell Biol. 2006. PMID: 16607538
-
Modified citrus pectin anti-metastatic properties: one bullet, multiple targets.Carbohydr Res. 2009 Sep 28;344(14):1788-91. doi: 10.1016/j.carres.2008.08.038. Epub 2008 Sep 26. Carbohydr Res. 2009. PMID: 19061992 Free PMC article. Review.
-
Extracellular galectin-3 in tumor progression and metastasis.Front Oncol. 2014 Jun 16;4:138. doi: 10.3389/fonc.2014.00138. eCollection 2014. Front Oncol. 2014. PMID: 24982845 Free PMC article. Review.
-
Research update on cell membrane camouflaged nanoparticles for cancer therapy.Front Bioeng Biotechnol. 2022 Aug 5;10:944518. doi: 10.3389/fbioe.2022.944518. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 35992357 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous